BLAINTRAVENOUSSOLUTION
Approved
Jul 2013
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
7
Data completeness
2/8 — Basic
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Octaplas is a human plasma protein solution administered intravenously, derived from pooled human plasma. It is indicated for plasma replacement in patients requiring urgent reversal of vitamin K antagonists or correction of coagulation factor deficiencies. The product contains a balanced mix of clotting factors and other plasma proteins that restore hemostatic function.
Peak
Octaplas is in peak lifecycle stage, indicating stable market presence and established team structures supporting mature commercialization efforts.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (7)
Observational Study of the Use of octaplasLG®.
Started Mar 2018
263 enrolled
Thrombotic Thrombocytopenic Purpura
Octaplas Adult TTP Trial
Started Jun 2017
1 enrolled
Thrombotic Thrombocytopenic Purpura
Evaluation of the Safety of Octaplas™ Versus Plasma in Patients Undergoing Orthotopic Liver Transplantation
Started Aug 2015
43 enrolled
CoagulopathyEndstage Liver Disease
Octaplas Pediatric Plasma Exchange Trial
Started Apr 2015
41 enrolled
Adverse Effects in the Therapeutic Use of Plasma Substitutes
Octaplas Pediatric Plasma Replacement Trial
Started Dec 2014
50 enrolled
Liver SurgeryLiver DysfunctionCoagulopathy+1 more
Worked on Octaplas at Octapharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.